Cover Image
市場調查報告書

攝護腺特異性抗原:開發中產品分析

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 369080
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
攝護腺特異性抗原:開發中產品分析 Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H1 2017
出版日期: 2017年06月20日 內容資訊: 英文 60 Pages
簡介

本報告提供以攝護腺特異性抗原為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關開發中之治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

攝護腺特異性抗原 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Advaxis, Inc.
  • Aeterna Zentaris Inc.
  • Bavarian Nordic A/S
  • Curevac AG
  • GenSpera, Inc.
  • Inovio Pharmaceuticals, Inc.
  • OncBioMune Pharmaceuticals Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0854TDB

Summary

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Prostate-specific antigen (PSA) is a glycoprotein enzyme encoded by the KLK3 gene. PSA is secreted by the epithelial cells of the prostate gland. It is hydrolyzes semenogelin-1 this leads to the liquefaction of the seminal coagulum.

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 2, 1 and 4 respectively. Similarly, the universities portfolio in Phase II stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology which include indications Prostate Cancer, Metastatic Hormone Refractory (Castration Resistant and Androgen-Independent) Prostate Cancer.

The latest report Prostate Specific Antigen - Pipeline Review, H1 2017, outlays comprehensive information on the Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)
  • The report reviews Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Overview
    • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Companies Involved in Therapeutics Development
    • Advaxis Inc
    • Aeterna Zentaris Inc
    • Bavarian Nordic A/S
    • Inovio Pharmaceuticals Inc
    • Inspyr Therapeutics Inc
    • OncBioMune Pharmaceuticals Inc
  • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Drug Profiles
    • ADXS-PSA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AEZS-120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target PSA for Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-114 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-115 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-5150 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody 1 to Inhibit PSA for Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonl Antibody to Inhibit PSA for Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Prostatac - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rilimogene galvacirepvec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Dormant Products
  • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Discontinued Products
  • Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 07, 2017: OncBioMune Protects ProscaVax Cancer Treatment Technology in Hong Kong
      • Jun 01, 2017: Protocol Submitted to FDA for Phase 2 Clinical Trial of ProscaVax as Immunotherapy for Early-Stage Prostate Cancer
      • May 03, 2017: OncBioMune Completes Enrollment in Phase 1 Trial of ProscaVax for Prostate Cancer
      • Apr 19, 2017: Bavarian Nordic Announces Initiation of Phase 2 Combination Trial of PROSTVAC, Ipilimumab and Nivolumab in Patients with Localized Prostate Cancer
      • Feb 02, 2017: OncBioMune Announces Presentation on ProscaVax at the 2017 American Association for Cancer Research Meeting
      • Jan 26, 2017: Latest Clinical Data from OncBioMune Supports Safety and Therapeutic Profile of ProscaVax for Prostate Cancer for Upcoming Phase 2 Clinical Trials
      • Jan 18, 2017: Departments of Urology and Oncology Approve Protocol for OncBioMune's Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico
      • Jan 10, 2017: OncBioMune Submitting Clinical Trial of World's First Early-Stage Prostate Cancer Vaccine to The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute
      • Jan 04, 2017: Bavarian Nordic Provides Update on Anticipated Timing of PROSPECT Study
      • Dec 28, 2016: Patients Pre-Screened for OncBioMune Pharmaceuticals Phase 2/3 Trial of ProscaVax for Prostate Cancer
      • Dec 12, 2016: OncBioMune Awarded Patent in Europe Protecting Novel Cancer Vaccine Technology
      • Dec 08, 2016: OncBioMune and the Clinical Trial Investigators Have Agreed Upon the Protocol for Their Phase 2 Trial of Novel Vaccine for Early Stage Prostate Cancer
      • Oct 24, 2016: Immunotherapy Expert Dr. Brian Barnett Joins OncBioMune Scientific Advisory Board
      • Oct 20, 2016: Advaxis Initiates Combination Portion of Phase 1/2 Study with Merck
      • Oct 19, 2016: OncBioMune Receives Notice of Patent Allowance for Novel Cancer Vaccine ProscaVax in Mexico
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Advaxis Inc, H1 2017
  • Pipeline by Aeterna Zentaris Inc, H1 2017
  • Pipeline by Bavarian Nordic A/S, H1 2017
  • Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Pipeline by Inspyr Therapeutics Inc, H1 2017
  • Pipeline by OncBioMune Pharmaceuticals Inc, H1 2017
  • Dormant Projects, H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top